A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
85
Enrollment
INDUSTRY
Sponsor class
Conditions
Non Small Cell Lung Cancer
Triple Negative Breast Cancer
Hodgkin Lymphoma
Head and Neck Squamous Cell Carcinoma
Malignant Melanoma
Interventions
DRUG:
CTX-8371
Sponsor
Compass Therapeutics